Garrison, Louis P. http://orcid.org/0000-0002-9468-4989
Schepman, Patricia http://orcid.org/0000-0001-9462-9261
Bushmakin, Andrew G. http://orcid.org/0000-0002-0082-6545
Robinson, Rebecca L. http://orcid.org/0000-0003-1490-0491
Tive, Leslie http://orcid.org/0000-0002-6386-0839
Hall, Jerry http://orcid.org/0000-0002-0184-661X
Dzingina, Mendwas http://orcid.org/0000-0002-6237-9250
Jackson, James http://orcid.org/0000-0002-4171-5390
Berry, Mia http://orcid.org/0000-0003-4683-2833
Cappelleri, Joseph C. http://orcid.org/0000-0001-9586-0748
Silverman, Stuart http://orcid.org/0000-0002-5313-1018
Funding for this research was provided by:
Pfizer
Eli Lilly and Company
Article History
Accepted: 5 June 2021
First Online: 5 July 2021
Declarations
:
: Louis P. Garrison and Stuart Silverman received consulting fees associated with this study from Pfizer and Eli Lilly and Company. Patricia Schepman, Andrew G. Bushmakin, Leslie Tive, Mendwas Dzingina, and Joseph C. Cappelleri are employees and stockholders of Pfizer Inc. Rebecca L. Robinson and Jerry Hall are employees and stockholders of Eli Lilly and Company. James Jackson and Mia Berry are employees of Adelphi Real World, who were paid consultants to Pfizer and Eli Lilly and Company with respect to this study.
: The OA DSP received a waiver by the Western Institutional Review Board.
: All participants (physicians and patients) provided informed consent. All authors approved the final version of the manuscript to be published.